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The title compound [1-(3,5-Dimethyl-2,3-dihydro-isoxazole-4-sulfonyl)-piperidin-4-
yl)-diphenyl-methanol was synthesized and the product obtained was characterized
by spectroscopic techniques and finally the structure was confirmed by X-ray diffrac-
tion studies. The compound crystallizes in the monoclinic crystal system with the space
group P21/c and with unit cell parameters a = 8.5280(6) Å, b = 25.223(4) Å, c =
10.7060(17) Å, β = 99.879(8)◦, and Z = 4. The structure reveals that the piperidine
ring is in chair conformation. The geometry around the S atom is distorted tetrahe-
dral. The structure exhibits both inter- and intramolecular hydrogen bonds of the type
O—H···N and C—H···O.
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1. Introduction
Despite major breakthroughs in many areas of modern medicine over past 100 years, the
successful treatment of cancer remains a significant challenge at the start of the 21st century.
Because it is difficult to discover novel agents that selectively kill tumor cells or inhibit
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their proliferation without the general toxicity, the use of traditional cancer chemotherapy
is still very limited. Antiproliferative and cytotoxic drugs play a major role in cancer
chemotherapy, whether used alone or in combination with other treatment modalities such
as surgery, radiation, and biological therapy. In the past 50 years, the mass screening of
either synthetic derivatives or natural products has led to the discovery of the currently
utilized anticancer drugs.
Cancer is a serious pathology and a substantial number of new antineoplastic agents
have been discovered. Considerable insight has been gained into the mechanisms by which
many of these compounds affect cellular growth and this knowledge has been used to
design new chemotherapeutic drugs [1–3]. Currently, combined anticancer therapies or
multiacting drugs are clinically preferred to traditional cytotoxic treatment, with the aim
of overcoming resistance and toxicity drawbacks. These events often prevent successful
treatment and are responsible for reduced survival times [4,5].
The accentuated interest in the piperidine class of opiate analgesics continues to be
expressed in the pharmaceutical community and biological properties of these agents have
been the subject of ongoing investigations [6]. The piperidine scaffold has wide-ranging
in its therapeutic uses as it is ubiquitously found in drugs. It is a key structural compo-
nent of successful anti-Parkinson’s drugs [7] and displays antipsychotic [8], antiviral [9],
metabolic [10], antimicrobial [11,12], antidepressants [13], acetylcholinesterase [14], anti-
malarial [15], and anticonvulsant activity [16,17]. Compounds containing amide bond can
alter the chemical properties, disposition, and biological activities of drugs [18]. Amides
are currently used as antidepressants, anti-inflammatory agents, antimalarial agents, an-
tipsychotic agents, antiviral agents, steroids, and general anesthetics [19].
2. Experimental
2.1. Preparation of
[1-(3,5-Dimethyl-2,3-dihydro-isoxazole-4-sulfonyl)-piperidin-4-yl)-diphenyl-methanol
A solution of diphenyl-(piperidin-4-yl)-methanol (0.5 g, 1.77 mmol) in dry dichloromethane
was taken and cooled to 0◦C–5◦C in an ice bath. Triethyl amine (0.537 g, 5.31 mmol) was
added to the cold mixture and stirred for 10 min, then 3,5-dimethyl-2,3-dihydro-isoxazole-
4-sulfonyl chloride (0.349 g, 1.77 mmol) was added. The mixture was allowed to room
temperature under stirring for 5–6 hr. The reaction mixture was monitored by TLC. Upon
completion, the solvent was removed under reduced pressure and residue was taken in
water and extracted with ethyl acetate. The organic layer was washed with 10% ammonium
chloride solution and finally water wash was given to organic layer and dried with anhydrous
sodium sulphate. The solvent was evaporated to get crude product which was purified by
column chromatography over silica gel (60–120 mesh) using hexane:ethyl acetate (8:2) as
an eluent. The obtained pure compound was dissolved in ethyl acetate. After 4–5 days,
white crystals developed due to the slow evaporation of solvent. The method employed for
synthesis is shown in Fig. 1.
1H NMR (DMSO, 400 MHz) δ: 7.47 (m, 4H, Ar-H), 7.23 (m, 4H, Ar-H), 7.09 (t, 2H,
Ar-H), 3.1 (d, 2H, -CH2), 3.61 (d, 2H, -CH2), 2.68 (t, 2H, -CH2), 2.62 (s, 3H, -CH3), 2.56
(s, 3H, -CH3), 2.4 (m, 1H, -CH), 2.31 (s, 2H, -CH2), 2.2 (s, 1H, -OH).
IR (KBr, cm−1): 3515, 1470, 1376, 1356, 1276.
MS (ESI) m/z: 427.00 (M + H+).
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Figure 1. Reaction scheme of the title compound.
Anal. calcd. for C23H26N2O4S (in%): C-64.77, H-6.14, N-6.57, S-7.52. Found C-64.75,
H-6.10, N-6.53, S-7.48.
2.2. Crystal Structure Determination
A single crystal of the title compound with dimensions of 0.27 × 0.23 × 0.20 mm was cho-
sen for X-ray diffraction study. The data were collected on a DIPLabo Image Plate diffrac-
tometer equipped with a normal focus, 3 kW sealed X-ray source (graphite-monochromated
MoKα). The crystal to detector distance was fixed at 120 mm with a detector area
441 × 240 mm. Thirty six frames of data were collected at room temperature by the
oscillation method. Each exposure of the image plate was set to a period of 400 sec. Suc-
cessive frames were scanned in steps of 5◦ per minute with an oscillation range of 5◦.
Image processing and data reduction were done using Denzo [20]. The reflections were
merged with scalepack. All of the frames could be indexed using a primitive monoclinic
lattice. The structure was solved by direct methods using SHELXS-97. All of the non-
hydrogen atoms were revealed in the first Fourier map itself. The structure was refined by
a full-matrix least-squares method with anisotropic temperature factors for non-hydrogen
atoms using SHELXL-97. The hydrogen atoms were fixed at chemically acceptable po-
sitions and were allowed to ride on their parent atoms. The residuals finally converged
to 0.0710. The details of the crystal structure and data refinement are given in Table 1.
The selected bond lengths and bond angles of the non-hydrogen atoms are given Table 2.
Figure 2 represents the ORTEP of the molecule with thermal ellipsoids drawn at 50%
probability.
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Table 1. Crystal data and structure refinement
Parameter Value
CCDC deposit no. 711047
Empirical formula C23H26N2O4S
Formula weight 426.52
Temperature 293(2) K
Wavelength 0.71073 Å
Crystal system, space group Monoclinic, P21/c
Unit cell dimensions a = 8.5280(6) Å
b = 25.223(4) Å
c = 10.7060(17) Å
β = 99.879(8)◦
Volume 2268.7(5) Å3
Z, Calculated density 4, 1.249 Mg/m3
Absorption coefficient 0.173 mm−1
F(000) 904
Crystal size 0.27 × 0.23 × 0.20 mm
Theta range for data collection 2.09◦ to 25.02◦
Limiting indices –9≤ h ≤ 9, –30≤ k ≤ 28, –10≤ l ≤ 10
Reflections collected/unique 5046/3108 [R(int) = 0.0276]
Refinement method Full-matrix least squares on F2
Data/restraints/parameters 3108/0/274
Goodness-of-fit on F2 1.068
Final R indices [I>2σ (I)] R1 = 0.0710, wR2 = 0.2137
R indices (all data) R1 = 0.0929, wR2 = 0.2420
Largest diff. peak and hole 0.350 and −0.334 e. Å−3
Table 2. Selected bond lengths and angles (Å, º)
N1-C6 1.474(5)
N1-C2 1.446(2)
N1-S7 1.610(3)
S7-O8 1.425(3)
S7-O9 1.426(3)
S7-C10 1.739(4)
O12-N13 1.405(5)
C6-N1-C2 112.7(3)
C6-N1-S7 120.4(2)
C2-N1-S7 118.2(2)
O8-S7-N1 120.1(2)
O8-S7-N1 107.3(2)
O9-S7-N1 106.8(2)
O9-S7-C10 107.4(2)
O8-S7-C10 105.7(2)
N1-S7-C10 109.3(2)
Synthesis, Characterization, Crystal and Molecular Structure Studies 147
Figure 2. ORTEP diagram of the molecule with thermal ellipsoids drawn at 50% probability.
3. Results and Discussion
A study of torsion angles, asymmetric parameters, and least-square plane calculations
reveals that the piperidine ring adopts a chair conformation with the atoms N1 and C4
deviating – 0.240(4) Å and 0.241(4) Å respectively from the Cremer and Pople plane
[21] defined by the atoms C2/C3/C5/C6. This is confirmed by the puckering parameters
Q = 0.5882(43) Å, θ = 180(44)◦, and φ = 289(91)◦. The bonds N1-S7 and C4-C17
make an angle of 82.1(2)◦ and 72.9(2)◦, respectively, with the Cremer and Pople plane of
the piperidine ring and thus are in equatorial plane of the piperidine ring. The isoxazole
ring is planar within the experimental limits. The dihedral angle between the least-squares
plane of the piperidine ring and isoxazole ring bridged by the sulfonyl group is 63.2(3)◦
which differs from the value of 49.80(1)◦ reported earlier [22]. The piperidine ring makes
and angle of 80.5(2)◦ and 53.4(2)◦ with the two phenyl rings [C19-C24] and [C25-C30],
respectively. The dihedral angle between the two phenyl rings bridged by the carbon atom
is 84.32(2)◦. The steric hindrance caused by the bulky sulfonyl group is more than the
steric effects caused by the dimethylphenyl ring which are attached on either side of the
piperidine ring. This is evident from the bond angle values of 112.7(3)◦ and 108.2(3)◦ for
C6-N1-C2 and C3-C4-C5, respectively.
The geometry around the S atom is distorted from regular tetrahedron, with the largest
deviation observed for the O-S-O [O9-S7-O8 = 120.1(2)◦] and O-S-N angle [O9-S7-N1
= 107.43(19)◦]. This widening of the angles is due to the repulsive interactions between
the S = O bonds and the nonbonded interactions involving the two S-O bonds and the
varied steric hindrance of the substituents. The structure thus has less steric interference.
The S = O bond distance lies within the expected range of 1.60-1.69 Å. The value of bond
angle for N1-S7-C10 is 109.3(2)◦ which is comparable with the ideal tetrahedral value of
109.47◦ is attributed to the Thorpe-Ingold effect [23]. The sulfonyl O atoms, O8 and O9
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Figure 3. Packing diagram of the molecule down the c-axis. The dashed lines indicate the hydrogen
bonds.
adopts –synclinal and +synclinal conformations, respectively, as indicated by the torsion
angle values of −35.7(4)◦ and 49.1(4)◦ for C6-N1-S-O9 and C2-N1-S7-O8, respectively.
The structure exhibits both inter- and intramolecular hydrogen bonds of the type O—H···N
which play a vital role in stabilizing the crystal structure. The intermolecular hydrogen
bond O18—H18···N13 has a length of 2.986(5) Å and an angle of 130◦ with symmetry
code –1 + x, 1/2 –y, –1/2 + z. The packing of the molecules when viewed down along
the c axis as shown in Fig. 3 indicates that the molecule exhibits layered stacking and are
interlinked by the intermolecular hydrogen bond to form a 1D chain.
4. Conclusion
The title compound [1-(3,5-Dimethyl-2,3-dihydro-isoxazole-4-sulfonyl)-piperidin-4-yl)-
diphenyl-methanol was synthesized and characterized by means of 1H NMR, FT-IR spec-
troscopic data. The molecular structure of the compound was determined by single crystal
X-ray diffraction technique. The crystal structure of the title compound reveals that the
piperidine ring adopts a chair conformation and the structure has a less steric interference.
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